A substrate specific functional polymorphism of human γ-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells

Pharmacogenetics

Volumn 14, Issue 8, 2004, Pages 557-567

  Cheng, Qing ^a   Wu, Bainan ^a   Kager, Leo ^a   Panetta, J Carl ^a   Zheng, Jie ^a   Pui, Ching Hon ^a   Relling, Mary V ^a   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukaemia; Human glutamyl hydrolase; Methotrexate; Methotrexate polyglutamates; Single nucleotide polymorphism

Indexed keywords

GAMMA GLUTAMYL HYDROLASE; GENOMIC DNA; METHOTREXATE; METHOTREXATE POLYGLUTAMATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AFRICAN AMERICAN; ARTICLE; BINDING AFFINITY; CATALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONFORMATION; CORRELATION ANALYSIS; DRUG ACCUMULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME MECHANISM; ENZYME SUBSTRATE; EXON; GENE FUNCTION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; KINETICS; LEUKEMIA CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

CATALYSIS; CLONING, MOLECULAR; DIPLOIDY; GAMMA-GLUTAMYL HYDROLASE; HUMANS; KINETICS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHOTREXATE; MUTAGENESIS, SITE-DIRECTED; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTRATE SPECIFICITY;

EID: 4143124340     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114761.78957.7e     Document Type: Article

References (51)

1. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907-912.
2. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335:1041-1048.
3. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11:5-14.
4. Camitta B, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, et al. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1994; 12:1383-1389.
5. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994; 12:740-747.
6. Niemeyer CM, Gelber RD, Tarbell NJ, Donnelly M, Clavell LA, Blattner SR, et al. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood 1991; 78:2514-2519.
7. Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 1998; 16:246-254.
8. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338:499-505.
9. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339:605-615.
10. Goldman ID, Lichtenstein NS, Oliverio VT. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 1968; 243:5007-5017.
11. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431-7457.
12. Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam Horm 1989; 45:263-335.
13. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996; 97:73-80.
14. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990; 76:44-49.
15. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994; 94:1996-2001.
16. Whitehead VM, Vuchich MJ, Lauer SJ, Mahoney D, Carroll AJ, Shuster JJ, et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1992; 80:1316-1323.
17. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994; 84:564-569.
18. Belkov VM, Krynetski EY, Schuetz JD, Yanishevski Y, Masson E, Mathew S, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 1999; 93:1643-1650.
19. Galivan J, Ryan T, Rhee M, Yao R, Chave K. Glutamyl hydrolase: properties and pharmacologic impact. Semin Oncol 1999; 26:33-37.
20. Rhee MS, Lindau-Shepard B, Chave KJ, Galivan J, Ryan TJ. Characterization of human cellular gamma-glutamyl hydrolase. Mol Pharmacol 1998; 53:1040-1046.
21. Panetta JC, Wall A, Pui CH, Relling MV, Evans WE. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res 2002; 8:2423-2429.
22. Yin D, Chave KJ, Macaluso CR, Galivan J, Yao R. Structural organization of the human gamma-glutamyl hydrolase gene. Gene 1999; 238:463-470.
23. Li H, Ryan TJ, Chave KJ, Van Roey P. Three-dimensional structure of human gamma-glutamyl hydrolase. A class I glatamine amidotransferase adapted for a complex substrate. J Biol Chem 2002; 277:24522-24529.
24. Chave KJ, Auger IE, Galivan J, Ryan TJ. Molecular modeling and site-directed mutagenesis define the catalytic motif in human gamma-glutamyl hydrolase. J Biol Chem 2000; 275:40365-40370.
25. Elsenhans B, Ahmad O, Rosenberg IH. Isolation and characterization of pteroylpolyglutamate hydrolase from rat intestinal mucosa. J Biol Chem 1984; 259:6364-6368.
26. Samuels LL, Goutas LJ, Priest DG, Piper JR, Sirotnak FM. Hydrolytic cleavage of methotrexate gamma-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse. Cancer Res 1986; 46:2230-2235.
27. Bhandari SD, Gregory JF, III, Renuart DR, Merritt AM. Properties of pteroylpolyglutamate hydrolase in pancreatic juice of the pig. J Nutr 1990; 120:467-475.
28. Yao R, Schneider E, Ryan TJ, Galivan J. Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci USA 1996; 93:10134-10138.
29. Pui CH, Relling MV, Sandlund JT, Downing JR, Campana D, Evans WE. Rational and design of total therapy study XV for newly diagnosed acute lymphoblastic leukemia. Annal Hematol 2004; 83(suppl 1):S124-S126.
30. Cheok MH, Yang W, Pui CH, Downing JR, Cheng C, Naeve CW, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet 2003; 34:85-90.
31. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-143.
32. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261:470-489.
33. Clark M, Cramer RD, Vanopdenbosch N. Validation of the general-purpose Tripos 5.2 force-field. J Comput Chem 1989; 10:982-1012.
34. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.
35. Chave KJ, Ryan TJ, Chmura SE, Galivan J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 2003; 319:167-175.
36. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
37. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
38. Brenner T, Pui C, Evans W. Pharmacogenomics of childhood acute lymphoblastic leukemia. Curr Opin Mol Ther 2002; 6:567-578.
39. Pui CH, Sandlund JT, Pei D, Rivera GK, Howard SC, Ribeiro RC, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003; 290:2001-2007.
40. Kadan-Lottick NS, Ness KK, Bhatia S, Gurney JG. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA 2003; 290:2008-2014.
41. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100:3832-3834.
42. Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, et al. Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His (27) and Arg (27) carriers. Clin Cancer Res 2001; 7:3416-3422.
43. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12:183-190.
44. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10:111-113.
45. Bagley PJ, Selnub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA 1998; 95:13217-13220.
46. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64:169-172.
47. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98:231-234.
48. Evans WE. Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics 2002; 12:181-182.
49. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62:1044-1051.
50. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359:1033-1034.
51. Mandola MV, Stoehlmacher J, Muller-weeks S, Cesarone G, Yu MC, Lenz HJ, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898-2904.